AK-OTOF

N/A

Report date: 2025/12/08 20:00:58

Base Information

Drug NameAK-OTOF
Drug Alias NameDual adeno-associated viral (AAV) vector-based gene therapy(Akouos)AAV vector-based gene therapy(Akouos)OTOF Gene Therapy (Akouos)AK-OTOFAA​​VAnc80-hOTOF
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVAnc80 vector
Mechanisms of ActionOtoferlin gene transference
TargetsOtoferlin
Therapy Area/IndicationsHearing Loss, SensorineuralHearing Loss, Bilateral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAkouos Inc
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And CompanyAkouos Inc
Inactive CompaniesN/A
Active IndicationsHearing Loss, SensorineuralHearing Loss, Bilateral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A